The coming flu season is the clearest indication yet that biopharma’s long-standing assumptions about predictability, ...

Editor’s Note: This deep dive was originally published Sept. 24, 2025, as a special edition of Biopharm Executive. Subscribe ...

New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that ...

Lynkuet is the first FDA-approved therapy that blocks both the neurokinin 1 and neurokinin 3 receptors to treat hot flashes.

Intellia earlier this year reported a similar grade 4 liver enzyme elevation associated with the gene therapy nexiguran ...

The takeover of its competitor, announced Sunday, could also bring some attention to Dyne Therapeutics, which has a similar ...

Executives from Eli Lilly, Merck and other companies foresee the FDA's new onshoring proposal being anything from a bureaucratic waste of time to a transformative program that will eliminate ...